The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V54425 | PLpro/RBD-IN-1 | 1282451-83-5 | PLpro/RBD-IN-1 (Compound 5) is a dual (bifunctional) inhibitor of SARS-CoV-2 PLpro and spike protein RBD, with IC50 of 7.197 μM and 8.673 μM respectively. |
|
V54412 | Plutavimab (COVI-AMG; STI-2020) | 2529854-88-2 | Plutavimab is a humanized IgG1-κ anti-SARS-CoV-2 antibody targeting the Spike (S) glycoprotein receptor-binding domain (RBD). |
|
V51271 | Pomotrelvir (PBI-0451) | 2713437-86-4 | SARS-CoV-2 3CL protease inhibitor |
|
V76079 | Propiolactone (β-propiolactone; 2-Oxetanone; Betaprone) | 57-57-8 | Propiolactone (β-propiolactone; 2-Oxetanone) is a viral chemical inactivator that causes the infectious inactivation of viruses. |
|
V39234 | Quipazine (2-(1-piperazinyl)quinoline) | 4774-24-7 | Quipazine is a 5-HT agonist that displaces 5-HT3R in rat endothelium with a Ki of 1.4 nM for [3H]GR65630. |
|
V39265 | Quipazine dimaleate | 150323-78-7 | Quipazine dimaleate is a 5-HT agonist, displacing 5-HT3R in rat endothelium [3H]GR65630 with a Ki of 1.4 nM. |
|
V54386 | Quisovalimab (AVTX-002; AEVI 002; SAR 252067) | 2427667-03-4 | Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody (mAb) against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) found in acute respiratory distress syndrome (ARDS). |
|
V85294 | RBT-9 | 123307-75-5 | |
|
V39194 | RdRP-IN-2 | 2863657-16-1 | RdRP-IN-2 is an RNA-dependent RNA polymerase (RdRp) inhibitor. |
|
V81279 | RdRP-IN-7 | RdRP-IN-7 is an RNA-dependent RNA polymerase (RdRP) inhibitor that shows inhibition of SARS-CoV-2 infection with IC50 of 8.2 μM, an IC90 of 14.1 μM, and a CC90 of 79.1 μM . | |
|
V39193 | Regdanvimab (CT-P59) | 2444308-95-4 | Regdanvimab (CT-P59) is a human monoclonal antibody (mAb) that targets the receptor-binding domain of the SARS-CoV-2 spike protein and blocks the interaction with ACE2 to prevent viral entry. |
|
V53288 | Remdesivir nucleoside monophosphate | 1911578-74-9 | Remdesivir nucleoside monophosphate is the metabolite of Remdesivir. |
|
V54419 | Rimteravimab (XVR011) | 2540797-21-3 | Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity combined with high stability, broad coverage, and silent Fc effector function to combat disease caused by SARS-CoV-2. |
|
V81304 | Ritonavir-13C,d3 (ABT 538-13C,d3; RTV-13C,d3) | Ritonavir-13C,d3 is a 13C- and deuterated-labeled Ritonavir. | |
|
V38267 | Romlusevimab (BRII-198) | 2509447-08-7 | Romlusevimab (BRII-198) is a neutralizing human IgG1 monoclonal antibody (mAb) directed against the SARS-CoV-2 coronavirus spike protein. |
|
V52578 | Saquinavir-d9 (saquinavir d9) | 1356355-11-7 | Saquinavir-d9 is the deuterium labelled form of Saquinavir. |
|
V54390 | SARS-CoV MPro-IN-1 | 2413716-71-7 | SARS-CoV MPro-IN-1 is a covalent inhibitor of SARS-CoV-2 3CLpro with IC50 of 40 nM. |
|
V37556 | SARS-CoV-2 3CLpro-IN-13 | 622794-09-6 | SARS-CoV-2 3CLpro-IN-13 is a potent inhibitor of SARS-CoV-2 3CL protease with IC50 of 21 nM. |
|
V81359 | SARS-CoV-2 3CLpro-IN-14 | SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally bioactive SARS-CoV-2 3CLpro inhibitor. | |
|
V54421 | SARS-CoV-2 3CLpro-IN-15 | 3156-41-0 | SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
